InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know

InMed Pharmaceuticals Inc. INM released its financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023, revealing sales of $1 million, an increase of 234% compared to $309,585 in Q3 2022.

Q3 FY 2023 Financial Highlights

  • Gross profit was $192,511 compared to $182,277 in Q3 FY 2022.

  • Net loss was $2 million compared to a loss of $3.5 million in Q3 FY 2022.

  • Cash and cash equivalents end of the period were $9.6 million

"The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol ("CBN") has completed a phase 2 clinical trial. We look forward to the data read out during 3Q and will then be in a better position to evaluate our strategic opportunities for the program," stated Eric A. Adams, president and CEO of InMed. "We are increasingly excited about the data we are seeing in our preclinical ocular and neurodegenerative disease programs where we are researching proprietary cannabinoid analogs in the treatment of various indications."

Price Action

InMed Pharmaceuticals shares were trading 5.17% higher at $1.22 during Tuesday’s pre-market session.

  • Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
  • Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
  • Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Share Price: $0.80
Min. Investment: $1,000
Valuation: $3.5B

Photo by Giorgio Trovato on Unsplash

Related News

Rare Cannabinoids Could Help Treat Atopic Dermatitis, Psoriasis, Pruritus And Acne: New Study

InMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?

InMed Pharmaceuticals Secures $6M Via Private Placement

 

INM Logo
INMInMed Pharmaceuticals Inc
$2.78-3.10%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
10.05
Growth
25.79
Quality
Not Available
Value
94.09
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...